Your browser is no longer supported. Please, upgrade your browser.
SNY Sanofi daily Stock Chart
Index- P/E21.54 EPS (ttm)1.74 Insider Own16.40% Shs Outstand2.60B Perf Week-0.90%
Market Cap97.23B Forward P/E12.61 EPS next Y2.97 Insider Trans0.00% Shs Float2.30B Perf Month-1.71%
Income4.54B PEG3.26 EPS next Q0.85 Inst Own10.20% Short Float0.15% Perf Quarter-11.88%
Sales37.28B P/S2.61 EPS this Y4.10% Inst Trans-0.33% Short Ratio1.48 Perf Half Y-10.68%
Book/sh23.45 P/B1.59 EPS next Y-2.79% ROA- Target Price51.67 Perf Year-23.15%
Cash/sh- P/C- EPS next 5Y6.60% ROE- 52W Range36.11 - 49.79 Perf YTD-8.65%
Dividend1.66 P/FCF- EPS past 5Y-4.40% ROI6.50% 52W High-24.90% Beta0.98
Dividend %4.44% Quick Ratio- Sales past 5Y0.50% Gross Margin68.90% 52W Low3.54% ATR0.51
Employees115631 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)40.67 Volatility0.91% 1.10%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.59 Prev Close37.76
ShortableYes LT Debt/Eq- EarningsOct 28 BMO Payout- Avg Volume2.26M Price37.39
Recom2.00 SMA20-1.82% SMA50-3.32% SMA200-5.48% Volume3,600,902 Change-0.98%
Sep-23-16Initiated Piper Jaffray Neutral
Sep-15-16Resumed JP Morgan Underweight
Sep-13-16Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-16Upgrade Berenberg Hold → Buy
May-03-16Downgrade HSBC Securities Buy → Hold
Dec-10-15Downgrade Exane BNP Paribas Neutral → Underperform
Dec-01-15Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-09-15Downgrade Bernstein Outperform → Mkt Perform
Oct-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-22-15Upgrade Citigroup Sell → Neutral
Apr-15-15Initiated Societe Generale Buy
Aug-03-12Downgrade Standpoint Research Buy → Hold
Jan-11-11Downgrade Jefferies Buy → Hold
Nov-16-09Initiated Deutsche Securities Buy
Oct-14-09Upgrade UBS Sell → Neutral
Aug-28-09Upgrade JP Morgan Neutral → Overweight
Jun-29-09Downgrade JP Morgan Overweight → Neutral
May-28-09Upgrade Citigroup Hold → Buy
Apr-30-09Upgrade JP Morgan Neutral → Overweight
Mar-23-09Upgrade Jefferies & Co Underperform → Hold
Oct-25-16 01:04PM  GlaxoSmithKlines 3Q16 Revenues Are Expected to Rise
01:04PM  How Much Revenue Growth Could Novo Record in 3Q16?
10:56AM  GlaxoSmithKlines 3Q16 Earnings: What to Expect
Oct-24-16 04:06PM  First Eagle Investments Comments on Sanofi
01:42PM  First Eagle Global Value Team 3rd Quarter Commentary
09:25AM  What to Watch in Sanofi's Third-Quarter Results
Oct-19-16 12:39PM  Biogen Expected to Report Modest Revenue Growth in 3Q16
10:06AM  Eli Lilly and Co.s 3Q16 Estimates: Endocrine Franchise
Oct-17-16 04:13PM  Eli Lilly, AbbVie Top 2017 Rankings; Pfizer, AstraZeneca Flailing
06:42AM  Moody's: French bond issuance volumes to be resilient in 2017, as large and repeat issuers will continue to drive the market at Moody's
Oct-14-16 10:10AM  Johnson & Johnsons 3Q16 Earnings: What to Expect
Oct-13-16 04:27PM  Is iBPMS the Secret Ingredient for Agile Digital Transformation?
12:03PM  WHO warns global tuberculosis fight is billions of dollars behind at MarketWatch
Oct-11-16 09:30AM  Sanofi Vaccines Unit Riding High on BARDA Zika Funding
08:21AM  Is Another Blockbuster Drug on the Way for Regeneron Pharmaceuticals, Inc.? at Motley Fool
Oct-10-16 05:47PM  Gilead's Patience Is Wearing Investors' Patience Thin
12:56AM  [$$] Insulin Prices Soar While Drugmakers Share Stays Flat at The Wall Street Journal
Oct-09-16 12:13PM  The Big Reason You Shouldn't Give Up on Big-Cap Biotech at Motley Fool
08:28AM  What's Behind Keryx Biopharmaceuticals' 28.6% Jump in September? at Motley Fool
Oct-07-16 07:26PM  3 Beaten-Up Big Pharma Stocks: Are They Bargains Now? at Motley Fool
06:02PM  [$$] Insulin-Price Increases Reflect Role of Health-Care Middlemen at The Wall Street Journal
04:21PM  BioMarin, Incyte, Kite Get Thumbs Up On Goldman Sachs Upgrade
10:28AM  What's Next for Alnylam Pharmaceuticals, Inc. After Its Phase 3 Failure? at Motley Fool
Oct-06-16 07:34PM  Sanofi Pasteur's offers world's first dengue vaccine
04:44PM  Ophthotech's Eye Disease Med Could Beat Down Rival Regeneron
12:38PM  Heres what a more than $2B loss in market value at Alnylam could mean locally at
06:54AM  Eli Lilly to Buy Boehringer's Vetmedica Pet Vaccines Unit
Oct-05-16 04:04PM  Eli Lilly Looks To Corral More Animal-Health Business Vs. Zoetis
03:33PM  SNY President Raab: We're Benefiting From Success of Mets
12:02PM  Take a Look at Sanofi
08:30AM  New Survey Reveals the Widespread and Serious Impact of Moderate-to-Severe Atopic Dermatitis on People Living with the Disease PR Newswire
08:04AM  AstraZeneca Heart Drug Brilinta Fails a Study; Shares Down
07:43AM  [$$] Eli Lilly to Buy Boehringer Ingelheim Pet Vaccines Portfolio at The Wall Street Journal
Oct-04-16 04:23PM  Which Biotechs Set Up For Q4 Boost From Drug Trial Results?
10:28AM  Sanofi to Seek U.S. Approval for First Dengue Vaccine in Months at Bloomberg
07:22AM  Zika vaccine race spurred by crisis and profit potential
Oct-03-16 06:30PM  Regeneron, Sanofi Report Drug Results (REGN, SNY) at Investopedia
10:06AM  Diabetes Care Market Is Expected to See Fast Growth
10:04AM  Novo Nordisk Expects to Witness Strong Growth from New Product Launches
Oct-01-16 02:00AM  Regeneron eczema drug reduces itch and anxiety, two studies show Reuters
02:00AM  Regeneron and Sanofi Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data Published in the New England Journal of Medicine PR Newswire
Sep-30-16 04:44PM  Why Investors Are Paying a Premium for Regeneron Pharmaceuticals, Inc. at Motley Fool
02:37PM  Chardan Rates Regeneron A Sell, Advises Caution
01:25PM  The Highest-Yielding Drug Stocks at Motley Fool
11:05AM  Understanding Strong Growth Trends in Insulin and Novo Nordisks Profitability
08:05AM  Regeneron Is a Late Entrant in Immuno-Oncology Space
Sep-29-16 03:04PM  Diabetes Care Market Expected to Offer Strong Growth for Novo Nordisk
01:34PM  The Diabetes Price War Claims Casualties at Bloomberg
Sep-28-16 08:03AM  3 Stocks to Avoid in Healthcare at Motley Fool
08:02AM  3 Top Dividend Stocks Selling for a Discount This Fall at Motley Fool
07:00AM  Looking Abroad for Quality Bargains at Morningstar
Sep-27-16 11:05AM  Pharmaceuticals Deal with End of Key Cystic Fibrosis Study
10:20AM  ETFs with exposure to Sanofi : September 27, 2016
09:30AM  The Zacks Analyst Blog Highlights: Teva Pharmaceutical Industries, Intel, Sanofi, Alphabet and Qualcomm
06:59AM  [$$] Corporate-Bond Buying Attracts Doubts as Growth Tool for Europe at The Wall Street Journal
Sep-26-16 04:32PM  Regeneron-Sanofi Could Beat Pfizer, Roche, AstraZeneca On Eczema
03:55PM  Regeneron, Sanofi Skin Disease Drug Under Priority Review
12:00PM  Sanofi gets $43 mln U.S. funding to spur Zika vaccine development
11:24AM  Pfizer: Split Decision at
10:05AM  Teva Pharmaceutical Leads in Global Generic Pharmaceutical Space
09:33AM  The Internet of Medical Things: 6 Stocks in Focus
07:15AM  FDA set to decide on two likely blockbuster drugs by Sanofi Genzyme at
03:26AM  Sanofi may win U.S. approval of $3 billion eczema drug by March
03:24AM  Sanofi may win U.S. approval of $3 bln eczema drug by March Reuters
01:00AM  Regeneron and Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA PR Newswire
Sep-23-16 05:04PM  Youve Heard about the EpiPen Debacle, but Have You Heard This?
07:15AM  Coverage initiated on Sanofi by Piper Jaffray
Sep-22-16 11:12AM  Hard to swallow: emerging markets get tougher for drugmakers
10:33AM  Buffett Stock Wells Fargo Falls Close to 52-Week Low Post Scandal
09:56AM  New Setback for Sanofi's Lantus Increases Need for M&A
Sep-21-16 03:04PM  Cone Snail Venom Could Inspire Fast-Acting Insulin For Diabetes at Forbes
Sep-20-16 02:00PM  Sanofi Sues Merck Over Patent Infringement
12:09PM  The 5 Top-Selling Drugs In The World
12:19AM  Business Watch at The Wall Street Journal
Sep-19-16 06:46PM  Sanofi in a State of Suspended Animation Until Boehringer Ingelheim Swap
11:19AM  [$$] Sanofi Files Suit Against Merck at The Wall Street Journal
10:47AM  Sanofi Fighting a Losing Battle, Sues Merck for Alleged Patent Infrigement
09:45AM  This Diabetes Breakthrough Is Great News or Terrible News, Depending on Your Perspective at Motley Fool
06:04AM  5 Things You Must Know Before the Market Opens Monday
Sep-17-16 03:00PM  There's something odd about the way insulin prices change
09:17AM  6 Flu Season Facts You Probably Don't Know at Motley Fool
Sep-16-16 10:30AM  Treatment Effects Maintained Over Six Years in Patients with Relapsing Remitting Multiple Sclerosis who Received Sanofi Genzymes Lemtrada® (alemtuzumab) in Clinical Trials Business Wire
10:00AM  MNKD: How MannKind's Stock Price Fell 28% in 6 Months at Investopedia
09:04AM  Pharma Stock Roundup: Acquisitions & Deals Pick Up Pace, Aerie Up on Positive Data
08:04AM  Analyst Price Targets and Recommendations for Sanofi
12:02AM  A 93-year-old drug that can cost more than a mortgage payment tells us everything that's wrong with American healthcare
Sep-15-16 03:02PM  Sanofi (SNY) Presents Positive Diabetes Data on iGlarLixi (revised)
11:11AM  A 93-year-old drug that some children can't live without tells us everything that's wrong with American healthcare
11:04AM  Sanofis Chase for Zika Virus Vaccine Could Drive Its Share Price
10:45AM  Results from 1,000-Patient, Global Real-World Patient-Reported Outcomes Study of Sanofi Genzymes Aubagio® (teriflunomide) in Patients with Relapsing Multiple Sclerosis Demonstrate High Levels of Treatment Satisfaction Business Wire
10:04AM  Sanofis Rare Disease Franchise Continues to Be a Revenue Boon
08:22AM  Toujeo® Demonstrates a More Stable Profile and Lower Within-day Variability Compared to Insulin Degludec CNW Group
08:04AM  Will Sanofi See More Growth from Its Blockbuster Insulin Drug?
05:23AM  Negative-Yielding Corporate Debt: Good for Your Wealth? at The Wall Street Journal
Sep-14-16 06:04PM  How Sanofis Various Franchises Performed in 2Q16
04:04PM  How Sanofis Franchises Could Perform into 2017
02:08PM  Understanding Sanofis Discounted Valuation
09:14AM  Sanofi (SNY) Presents Positive Diabetes Data on iGlarLixi
Sep-13-16 03:21PM  Is This Lexicon Pharmaceuticals' Year? at Motley Fool
11:04AM  GSK Optimistic about Future of Its Consumer Healthcare Segment
Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. It offers Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; Toujeo, an insulin glargine; and Afrezza, an inhaled insulin. The company also provides Praluent, a human monoclonal antibody; and Multaq, a multichannel blocker with anti-arrhythmic properties. In addition, it offers Cerezyme, an enzyme replacement therapy to treat gaucher disease; cerdelga, an oral therapy for Gaucher disease Type 1; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis Type 1, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for breast, prostate, gastric, lungs, and head and neck cancer treatment; Eloxatin for the treatment of stage III colon cancer; Thymoglobulin to treat acute rejection; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix/Iscover for atherothrombosis and acute coronary syndrome; Lovenox/Clexane for the treatment of venous thromboembolism; Aprovel/Avapro/Karvea for hypertension and nephropathy; Renagel/Renvela to treat chronic kidney disease; Allegra/Telfast to treat seasonal allergic rhinitis and uncomplicated hives; Stilnox/Ambien/Myslee for insomnia treatment; and Synvisc/Synvisc-One for the treatment of osteoarthritis pain. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerJun 14Buy363.8664,73123,552,85923,418,396Jun 16 05:47 PM
Sanofi10% OwnerFeb 17Buy393.7180,00031,496,72823,353,665Feb 18 05:45 PM
Sanofi10% OwnerFeb 16Buy391.2381,15731,751,18223,273,665Feb 18 05:45 PM
Sanofi10% OwnerJan 12Buy465.0483,93839,034,66023,192,508Jan 14 05:46 PM
Sanofi10% OwnerNov 03Buy10.00900,0009,000,0003,218,899Nov 05 02:37 PM